CRISPR Therapeutics AG

CEO’s latest buy of 20,625 CRISPR shares signals strong confidence in the biotech’s gene‑editing pipeline and new capital raise, hinting at future upside for investors.

CEO’s buy‑back of 19,250 CRISPR Therapeutics shares after a $550 M convertible note raise signals confidence and could boost future R&D, while dilution risks stay in view.

CRISPR Therapeutics insider buying: Naimish Patel’s April purchase shows scientific leadership confidence amid CEO sell‑offs, offering insight for investors.

CRISPR CFO Prasad Raju’s simultaneous buy‑sell trade shows disciplined insider trading that captures short‑term gains while backing the company’s gene‑editing pipeline and growth prospects.

Insider trades reveal confidence in CRISPR Therapeutics’ gene‑editing platform; phase‑II oncology and rare‑disease data show high efficacy, low risk, and strong regulatory momentum.